No recent analyst price targets found for CLVLY.
Latest News for CLVLY
SCENESSE® approved for EPP in Canada
Health Canada NOC enables treatment for porphyria, metabolic disorder Health Canada NOC enables treatment for porphyria, metabolic disorder
CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo study EMA emphasised its “totality of evidence” approach central photographic review and validated disease assessment tools agreed CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy CUV107 study (n=300) to commence in 2H 2026 MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CLVLY.
Senate Trading
No Senate trades found for CLVLY.
U.S. House Trading
No House trades found for CLVLY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.